{"pmid":32360584,"pmcid":"PMC7192109","title":"Possible use of the mucolytic drug, bromhexine hydrochloride, as a prophylactic agent against SARS-CoV-2 infection based on its action on the Transmembrane Serine Protease 2.","text":["Possible use of the mucolytic drug, bromhexine hydrochloride, as a prophylactic agent against SARS-CoV-2 infection based on its action on the Transmembrane Serine Protease 2.","Pharmacol Res","Habtemariam, Solomon","Nabavi, Seyed Fazel","Ghavami, Saeid","Cismaru, Cosmin Andrei","Neagoe, Ioana Berindan","Nabavi, Seyed Mohammad","32360584"],"journal":"Pharmacol Res","authors":["Habtemariam, Solomon","Nabavi, Seyed Fazel","Ghavami, Saeid","Cismaru, Cosmin Andrei","Neagoe, Ioana Berindan","Nabavi, Seyed Mohammad"],"date":"2020-05-04T11:00:00Z","year":2020,"_id":"32360584","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.phrs.2020.104853","e_drugs":["Bromhexine","Serine"],"topics":["Treatment"],"weight":1,"_version_":1666138495932956672,"score":9.490897,"similar":[{"pmid":32408547,"title":"Virtual Screening of Natural Products against Type II Transmembrane Serine Protease (TMPRSS2), the Priming Agent of Coronavirus 2 (SARS-CoV-2).","text":["Virtual Screening of Natural Products against Type II Transmembrane Serine Protease (TMPRSS2), the Priming Agent of Coronavirus 2 (SARS-CoV-2).","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused about 2 million infections and is responsible for more than 100,000 deaths worldwide. To date, there is no specific drug registered to combat the disease it causes, named coronavirus disease 2019 (COVID-19). In the current study, we used an in silico approach to screen natural compounds to find potent inhibitors of the host enzyme transmembrane protease serine 2 (TMPRSS2). This enzyme facilitates viral particle entry into host cells, and its inhibition blocks virus fusion with angiotensin-converting enzyme 2 (ACE2). This, in turn, restricts SARS-CoV-2 pathogenesis. A three-dimensional structure of TMPRSS2 was built using SWISS-MODEL and validated by RAMPAGE. The natural compounds library Natural Product Activity and Species Source (NPASS), containing 30,927 compounds, was screened against the target protein. Two techniques were used in the Molecular Operating Environment (MOE) for this purpose, i.e., a ligand-based pharmacophore approach and a molecular docking-based screening. In total, 2140 compounds with pharmacophoric features were retained using the first approach. Using the second approach, 85 compounds with molecular docking comparable to or greater than that of the standard inhibitor (camostat mesylate) were identified. The top 12 compounds with the most favorable structural features were studied for physicochemical and ADMET (absorption, distribution, metabolism, excretion, toxicity) properties. The low-molecular-weight compound NPC306344 showed significant interaction with the active site residues of TMPRSS2, with a binding energy score of -14.69. Further in vitro and in vivo validation is needed to study and develop an anti-COVID-19 drug based on the structures of the most promising compounds identified in this study.","Molecules","Rahman, Noor","Basharat, Zarrin","Yousuf, Muhammad","Castaldo, Giuseppe","Rastrelli, Luca","Khan, Haroon","32408547"],"abstract":["Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused about 2 million infections and is responsible for more than 100,000 deaths worldwide. To date, there is no specific drug registered to combat the disease it causes, named coronavirus disease 2019 (COVID-19). In the current study, we used an in silico approach to screen natural compounds to find potent inhibitors of the host enzyme transmembrane protease serine 2 (TMPRSS2). This enzyme facilitates viral particle entry into host cells, and its inhibition blocks virus fusion with angiotensin-converting enzyme 2 (ACE2). This, in turn, restricts SARS-CoV-2 pathogenesis. A three-dimensional structure of TMPRSS2 was built using SWISS-MODEL and validated by RAMPAGE. The natural compounds library Natural Product Activity and Species Source (NPASS), containing 30,927 compounds, was screened against the target protein. Two techniques were used in the Molecular Operating Environment (MOE) for this purpose, i.e., a ligand-based pharmacophore approach and a molecular docking-based screening. In total, 2140 compounds with pharmacophoric features were retained using the first approach. Using the second approach, 85 compounds with molecular docking comparable to or greater than that of the standard inhibitor (camostat mesylate) were identified. The top 12 compounds with the most favorable structural features were studied for physicochemical and ADMET (absorption, distribution, metabolism, excretion, toxicity) properties. The low-molecular-weight compound NPC306344 showed significant interaction with the active site residues of TMPRSS2, with a binding energy score of -14.69. Further in vitro and in vivo validation is needed to study and develop an anti-COVID-19 drug based on the structures of the most promising compounds identified in this study."],"journal":"Molecules","authors":["Rahman, Noor","Basharat, Zarrin","Yousuf, Muhammad","Castaldo, Giuseppe","Rastrelli, Luca","Khan, Haroon"],"date":"2020-05-16T11:00:00Z","year":2020,"_id":"32408547","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.3390/molecules25102271","keywords":["coronavirus","docking","drug design","natural product","serine protease"],"e_drugs":["Serine","camostat"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666897319103037440,"score":83.56246},{"pmid":32334052,"pmcid":"PMC7175911","title":"Repurposing the mucolytic cough suppressant and TMPRSS2 protease inhibitor bromhexine for the prevention and management of SARS-CoV-2 infection.","text":["Repurposing the mucolytic cough suppressant and TMPRSS2 protease inhibitor bromhexine for the prevention and management of SARS-CoV-2 infection.","Pharmacol Res","Maggio, Roberto","Corsini, Giovanni U","32334052"],"journal":"Pharmacol Res","authors":["Maggio, Roberto","Corsini, Giovanni U"],"date":"2020-04-26T11:00:00Z","year":2020,"_id":"32334052","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.phrs.2020.104837","keywords":["bromhexine","covid-19","pandemic","tmprss2"],"e_drugs":["Bromhexine"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138494003576834,"score":80.026566},{"pmid":32469279,"title":"Withanone and withaferin-A are predicted to interact with transmembrane protease serine 2 (TMPRSS2) and block entry of SARS-CoV-2 into cells.","text":["Withanone and withaferin-A are predicted to interact with transmembrane protease serine 2 (TMPRSS2) and block entry of SARS-CoV-2 into cells.","Coronavirus disease 2019 (COVID-19) initiated in December 2019 in Wuhan, China, and became pandemic causing high fatality and disrupted normal life calling world almost to a halt. Causative agent is a novel coronavirus called Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/2019-nCoV). While new line of drug/vaccine development has been initiated world-wide, in the current scenario of high infected numbers, severity of the disease and high morbidity, repurposing of the existing drugs is heavily explored. Here, we used a homology-based structural model of transmembrane protease serine 2 (TMPRSS2), a cell surface receptor, required for entry of virus to the target host cell. Using the strengths of molecular docking and molecular dynamics simulations, we examined the binding potential of Withaferin-A (Wi-A), Withanone (Wi-N) and Caffeic Acid Phenethyl Ester to TPMRSS2 in comparison to its known inhibitor, Camostat mesylate. We found that both Wi-A and Wi-N could bind and stably interact at the catalytic site of TMPRSS2. Wi-N showed stronger interactions with TMPRSS2 catalytic residues than Wi-A, and also able to induce changes in its allosteric site. Furthermore, we investigated the effect of Wi-N on TMPRSS2 expression in MCF7 cells and found remarkable downregulation of TMPRSS2 mRNA in treated cells predicting dual action of Wi-N to block SARS-CoV-2 entry to the host cells. Since the natural compounds are easily available/affordable, they may even offer a timely therapeutic/preventive value for the management of SARS-CoV-2 pandemic. We also report that Wi-A/Wi-N content varies in different parts of Ashwagandha and warrants careful attention for their use.","J Biomol Struct Dyn","Kumar, Vipul","Dhanjal, Jaspreet Kaur","Bhargava, Priyanshu","Kaul, Ashish","Wang, Jia","Zhang, Huayue","Kaul, Sunil C","Wadhwa, Renu","Sundar, Durai","32469279"],"abstract":["Coronavirus disease 2019 (COVID-19) initiated in December 2019 in Wuhan, China, and became pandemic causing high fatality and disrupted normal life calling world almost to a halt. Causative agent is a novel coronavirus called Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/2019-nCoV). While new line of drug/vaccine development has been initiated world-wide, in the current scenario of high infected numbers, severity of the disease and high morbidity, repurposing of the existing drugs is heavily explored. Here, we used a homology-based structural model of transmembrane protease serine 2 (TMPRSS2), a cell surface receptor, required for entry of virus to the target host cell. Using the strengths of molecular docking and molecular dynamics simulations, we examined the binding potential of Withaferin-A (Wi-A), Withanone (Wi-N) and Caffeic Acid Phenethyl Ester to TPMRSS2 in comparison to its known inhibitor, Camostat mesylate. We found that both Wi-A and Wi-N could bind and stably interact at the catalytic site of TMPRSS2. Wi-N showed stronger interactions with TMPRSS2 catalytic residues than Wi-A, and also able to induce changes in its allosteric site. Furthermore, we investigated the effect of Wi-N on TMPRSS2 expression in MCF7 cells and found remarkable downregulation of TMPRSS2 mRNA in treated cells predicting dual action of Wi-N to block SARS-CoV-2 entry to the host cells. Since the natural compounds are easily available/affordable, they may even offer a timely therapeutic/preventive value for the management of SARS-CoV-2 pandemic. We also report that Wi-A/Wi-N content varies in different parts of Ashwagandha and warrants careful attention for their use."],"journal":"J Biomol Struct Dyn","authors":["Kumar, Vipul","Dhanjal, Jaspreet Kaur","Bhargava, Priyanshu","Kaul, Ashish","Wang, Jia","Zhang, Huayue","Kaul, Sunil C","Wadhwa, Renu","Sundar, Durai"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32469279","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1080/07391102.2020.1775704","keywords":["ashwagandha","covid-19","caffeic acid phenethyl ester","honey bee","transmembrane protease serine 2 (tmprss2)","withaferin-a","withanone","binding","inhibition","molecular docking","propolis"],"locations":["Wuhan","China","Withanone"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["6,7-epoxy-5,17-dihydroxy-1-oxowitha-2,24-dienolide","camostat","withaferin A","caffeic acid phenethyl ester"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668420887316004864,"score":70.496185},{"pmid":32468052,"title":"Pancancer analysis of transmembrane protease serine 2 and cathepsin L that mediate cellular SARSCoV2 infection leading to COVID-19.","text":["Pancancer analysis of transmembrane protease serine 2 and cathepsin L that mediate cellular SARSCoV2 infection leading to COVID-19.","Severe acute respiratory syndrome (SARS) coronavirus2 (SARSCoV2) is the cause of a new disease (COVID19) which has evolved into a pandemic during the first half of 2020. Older age, male sex and certain underlying diseases, including cancer, appear to significantly increase the risk for severe COVID19. SARSCoV2 infection of host cells is facilitated by the angiotensinconverting enzyme 2 (ACE2), and by transmembrane protease serine 2 (TMPRSS2) and other host cell proteases such as cathepsin L (CTSL). With the exception of ACE2, a systematic analysis of these two other SARSCoV2 infection mediators in malignancies is lacking. Here, we analysed genetic alteration, RNA expression, and DNA methylation of TMPRSS2 and CTSL across a wide spectrum of tumors and controls. TMPRSS2 was overexpressed in cervical squamous cell carcinoma and endocervical adenocarcinoma, colon adenocarcinoma, prostate adenocarcinoma (PRAD), rectum adenocarcinoma (READ), uterine corpus endometrial carcinoma and uterine carcinosarcoma, with PRAD and READ exhibiting the highest expression of all cancers. CTSL was upregulated in lymphoid neoplasm diffuse large Bcell lymphoma, oesophageal carcinoma, glioblastoma multiforme, head and neck squamous cell carcinoma, lower grade glioma, pancreatic adenocarcinoma, skin cutaneous melanoma, stomach adenocarcinoma, and thymoma. Hypomethylation of both genes was evident in most cases where they have been highly upregulated. We have expanded on our observations by including data relating to mutations and copy number alterations at pancancer level. The novel hypotheses that are stemming out of these data need to be further investigated and validated in large clinical studies.","Int J Oncol","Katopodis, Periklis","Anikin, Vladimir","Randeva, Harpal S","Spandidos, Demetrios A","Chatha, Kamaljit","Kyrou, Ioannis","Karteris, Emmanouil","32468052"],"abstract":["Severe acute respiratory syndrome (SARS) coronavirus2 (SARSCoV2) is the cause of a new disease (COVID19) which has evolved into a pandemic during the first half of 2020. Older age, male sex and certain underlying diseases, including cancer, appear to significantly increase the risk for severe COVID19. SARSCoV2 infection of host cells is facilitated by the angiotensinconverting enzyme 2 (ACE2), and by transmembrane protease serine 2 (TMPRSS2) and other host cell proteases such as cathepsin L (CTSL). With the exception of ACE2, a systematic analysis of these two other SARSCoV2 infection mediators in malignancies is lacking. Here, we analysed genetic alteration, RNA expression, and DNA methylation of TMPRSS2 and CTSL across a wide spectrum of tumors and controls. TMPRSS2 was overexpressed in cervical squamous cell carcinoma and endocervical adenocarcinoma, colon adenocarcinoma, prostate adenocarcinoma (PRAD), rectum adenocarcinoma (READ), uterine corpus endometrial carcinoma and uterine carcinosarcoma, with PRAD and READ exhibiting the highest expression of all cancers. CTSL was upregulated in lymphoid neoplasm diffuse large Bcell lymphoma, oesophageal carcinoma, glioblastoma multiforme, head and neck squamous cell carcinoma, lower grade glioma, pancreatic adenocarcinoma, skin cutaneous melanoma, stomach adenocarcinoma, and thymoma. Hypomethylation of both genes was evident in most cases where they have been highly upregulated. We have expanded on our observations by including data relating to mutations and copy number alterations at pancancer level. The novel hypotheses that are stemming out of these data need to be further investigated and validated in large clinical studies."],"journal":"Int J Oncol","authors":["Katopodis, Periklis","Anikin, Vladimir","Randeva, Harpal S","Spandidos, Demetrios A","Chatha, Kamaljit","Kyrou, Ioannis","Karteris, Emmanouil"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32468052","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.3892/ijo.2020.5071","topics":["Mechanism"],"weight":1,"_version_":1668167110086361088,"score":65.9622},{"pmid":32294495,"pmcid":"PMC7152897","title":"Chloroquine as a prophylactic agent against COVID-19?","text":["Chloroquine as a prophylactic agent against COVID-19?","Int J Antimicrob Agents","Gendrot, Mathieu","Javelle, Emilie","Le Dault, Erwan","Clerc, Axelle","Savini, Helene","Pradines, Bruno","32294495"],"journal":"Int J Antimicrob Agents","authors":["Gendrot, Mathieu","Javelle, Emilie","Le Dault, Erwan","Clerc, Axelle","Savini, Helene","Pradines, Bruno"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32294495","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.ijantimicag.2020.105980","e_drugs":["Chloroquine"],"topics":["Treatment"],"weight":1,"_version_":1666138494442930176,"score":54.433685}]}